Updates in diagnostic immunohistochemistry in endometrial carcinoma

Seminars in Diagnostic Pathology

Volumn 31, Issue 3, 2014, Pages 205-215

  Chiang, Sarah ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clear cell; Endometrial carcinoma; Endometrioid; Immunohistochemistry; Serous; Undifferentiated

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; KI 67 ANTIGEN; MISMATCH REPAIR PROTEIN PMS2; MONOCLONAL ANTIBODY B.72.3; NAPSIN A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROSTAGLANDIN E RECEPTOR 4; PROTEIN BAF250A; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P16; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER GRADING; CLEAR CELL CARCINOMA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MIXED TUMOR; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNDIFFERENTIATED CARCINOMA;

CLEAR CELL; ENDOMETRIAL CARCINOMA; ENDOMETRIOID; IMMUNOHISTOCHEMISTRY; SEROUS; UNDIFFERENTIATED;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84902489415     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2014.03.002     Document Type: Article

References (77)

1. Gilks C.B., Oliva E., Soslow R.A. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013, 37:874-881.
2. Kandoth C., Schultz N., Cherniack A.D., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
3. Hoang L.N., McConechy M.K., Kobel M., et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 2013, 37:1421-1432.
4. Bartosch C., Manuel Lopes J., Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 2011, 18:415-437.
5. Dabbs D.J. Diagnostic Immunohistochemistry: Theranostic and Genomic Applications 2010, Saunders/Elsevier, Philadelphia, PA.
6. Reid-Nicholson M., Iyengar P., Hummer A.J., Linkov I., Asher M., Soslow R.A. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006, 19:1091-1100.
7. Dabbs D.J., Sturtz K., Zaino R.J. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol 1996, 27:172-177.
8. McCluggage W.G., Sumathi V.P., McBride H.A., Patterson A. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 2002, 21:11-15.
9. Park K.J., Bramlage M.P., Ellenson L.H., Pirog E.C. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation. Appl Immunohistochem Mol Morphol 2009, 17:8-11.
10. Wani Y., Notohara K., Saegusa M., Tsukayama C. Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation. Hum Pathol 2008, 39:1072-1079.
11. Darvishian F., Hummer A.J., Thaler H.T., et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004, 28:1568-1578.
12. Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol 1998, 29:924-931.
13. Soslow R.A., Shen P.U., Chung M.H., Isacson C., Baergen R.N. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype. Int J Gynecol Pathol 2000, 19:329-334.
14. Hoang L.N., Han G., McConechy M., et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1beta and oestrogen receptor. Histopathology 2014, 64:585-596.
15. Mhawech-Fauceglia P., Yan L., Liu S., Pejovic T. ER+/PR+/TFF3+/IMP3-immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases. Histopathology 2013, 62:976-985.
16. Halperin R., Zehavi S., Habler L., Hadas E., Bukovsky I., Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001, 22:122-126.
17. Alvarez T., Miller E., Duska L., Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?. Am J Surg Pathol 2012, 36:753-761.
18. Riethdorf L., Begemann C., Riethdorf S., Milde-Langosch K., Löning T. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis. Virchows Arch 1996, 428:47-51.
19. Alkushi A., Kobel M., Kalloger S.E., Gilks C.B. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010, 29:343-350.
20. Egan J.A., Ionescu M.C., Eapen E., Jones J.G., Marshall D.S. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004, 23:119-122.
21. Lax S.F., Kendall B., Tashiro H., Slebos R.J., Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000, 88:814-824.
22. Soslow R.A., Shen P.U., Chung M.H., Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998, 17:129-134.
23. Zannoni G.F., Vellone V.G., Arena V., et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 2010, 457:27-34.
24. Fukuchi T., Sakamoto M., Tsuda H., Maruyama K., Nozawa S., Hirohasi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998, 58:3526-3528.
25. Nei H., Saito T., Yamasaki H., Mizumoto H., Ito E., Kudo R. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog 1999, 25:207-218.
26. Schlosshauer P.W., Ellenson L.H., Soslow R.A. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002, 15:1032-1037.
27. Yemelyanova A., Ji H., Shih Ie M., Wang T.L., Wu L.S., Ronnett B.M. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009, 33:1504-1514.
28. Bussaglia E., del Rio E., Matias-Guiu X., Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000, 31:312-317.
29. Obata K., Morland S.J., Watson R.H., et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998, 58:2095-2097.
30. Risinger J.I., Hayes A.K., Berchuck A., et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997, 57:4736-4738.
31. Simpkins S.B., Peiffer-Schneider S., Mutch D.G., Gersell D., Goodfellow P.J. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 1998, 71:391-395.
32. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997, 57:3935-3940.
33. Yokoyama Y., Wan X., Shinohara A., et al. Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med 2000, 6:47-50.
34. Maiques O., Santacana M., Valls J., et al. Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Hum Pathol 2014, 45:522-532.
35. Garg K., Broaddus R.R., Soslow R.A., Urbauer D.L., Levine D.A., Djordjevic B. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012, 31:48-56.
36. de Leeuw W.J., Dierssen J., Vasen H.F., et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000, 192:328-335.
37. Modica I., Soslow R.A., Black D., Tornos C., Kauff N., Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 2007, 31:744-751.
38. Peiro G., Diebold J., Lohse P., et al. Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 2002, 33:347-354.
39. Allo G., Bernardini M.Q., Wu R.C., et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 2014, 27:255-261.
40. Zhang Z.M., Xiao S., Sun G.Y., et al. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma. Int J Gynecol Cancer 2014, 24:534-540.
41. Sherman M.E., Bur M.E., Kurman R.J. p53 In endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26:1268-1274.
42. Tashiro H., Isacson C., Levine R., Kurman R.J., Cho K.R., Hedrick L. p53 Gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997, 150:177-185.
43. Zheng W., Khurana R., Farahmand S., Wang Y., Zhang Z.F., Felix J.C. p53 Immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998, 22:1463-1473.
44. Al Kushi A., Lim P., Aquino-Parsons C., Gilks C.B. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 2002, 15:365-371.
45. Carcangiu M.L., Chambers J.T., Voynick I.M., Pirro M., Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 1990, 94:247-254.
46. Chambers J.T., Carcangiu M.L., Voynick I.M., Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 1990, 94:255-260.
47. Vang R., Whitaker B.P., Farhood A.I., Silva E.G., Ro J.Y., Deavers M.T. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001, 20:252-259.
48. Dallenbach-Hellweg G., Lang-Averous G., Hahn U. The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas. APMIS Suppl 1991, 23:91-99.
49. Coosemans A., Moerman P., Verbist G., et al. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol 2008, 111:502-508.
50. Dupont J., Wang X., Marshall D.S., et al. Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004, 94:449-455.
51. Acs G., Pasha T., Zhang P.J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004, 23:110-118.
52. Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998, 29:551-558.
53. Arai T., Watanabe J., Kawaguchi M., et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer 2006, 16:391-395.
54. Fadare O., Gwin K., Desouki M.M., et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol 2013, 26:1101-1110.
55. Kalloger S.E., Kobel M., Leung S., et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011, 24:512-521.
56. Vang R., Barner R., Wheeler D.T., Strauss B.L. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol 2004, 23:223-233.
57. Fadare O., Renshaw I.L., Liang S.X. Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J Cancer 2012, 3:129-136.
58. Wiegand K.C., Lee A.F., Al-Agha O.M., et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011, 224:328-333.
59. Nelson G.S., Pink A., Lee S., et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol 2013, 131:309-314.
60. Carcangiu M.L., Radice P., Casalini P., Bertario L., Merola M., Sala P. Lynch syndrome-related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int J Surg Pathol 2010, 18:21-26.
61. Yamamoto S., Tsuda H., Aida S., Shimazaki H., Tamai S., Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007, 38:1074-1080.
62. Fadare O., Liang S.X. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol 2012, 20:580-587.
63. Fadare O., Desouki M.M., Gwin K., et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol 2014, 38:189-196.
64. Tatnell P.J., Powell D.J., Hill J., Smith T.S., Tew D.G., Kay J. Napsins: new human aspartic proteinases. Distinction between two closely related genes. FEBS Lett 1998, 441:43-48.
65. Tafe L.J., Garg K., Chew I., Tornos C., Soslow R.A. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010, 23:781-789.
66. Altrabulsi B., Malpica A., Deavers M.T., Bodurka D.C., Broaddus R., Silva E.G. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005, 29:1316-1321.
67. Abeler V.M., Kjorstad K.E., Nesland J.M. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer 1991, 68:98-105.
68. Romero-Perez L., Lopez-Garcia M.A., Diaz-Martin J., et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol 2013, 26:1514-1524.
69. Broaddus R.R., Lynch H.T., Chen L.M., et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006, 106:87-94.
70. Clement P.B., Young R.H. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2002, 9:145-184.
71. Ambros R.A., Ballouk F., Malfetano J.H., Ross J.S. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994, 18:569-575.
72. Zaino R.J., Kurman R.J., Brunetto V.L., et al. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. Am J Surg Pathol 1998, 22:1379-1385.
73. Esteller M., Garcia A., Martinez-Palones J.M., Xercavins J., Reventos J. Clinicopathologic features and genetic alterations in endometrioid carcinoma of the uterus with villoglandular differentiation. Am J Clin Pathol 1999, 111:336-342.
74. Murray S.K., Young R.H., Scully R.E. Uterine endometrioid carcinoma with small nonvillous papillae: an analysis of 26 cases of a favorable-prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol 2000, 8:279-289.
75. Soslow R.A. High-grade endometrial carcinomas-strategies for typing. Histopathology 2013, 62:89-110.
76. Silva E.G., Deavers M.T., Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology 2007, 39:134-138.
77. Tavassoli F.A., Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, IARC Press, Lyon.